Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy.

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Endothelial Dysfunction 100%
• C Reactive Protein 50%
• Plasminogen Activator Inhibitor 1 50%
• Intercellular Adhesion Molecule 1 50%
• E-Selectin 50%
• Vascular Cell Adhesion Molecule 1 50%
• Normal Human 16%
• Cardiovascular Risk 16%
• Tissue Plasminogen Activator 16%
• Human Immunodeficiency Virus Infection 16%
• Atherogenesis 16%
• Virus RNA 16%

Immunology and Microbiology

• Human Immunodeficiency Virus 100%
• C-Reactive Protein 50%
• Intercellular Adhesion Molecule 1 50%
• VCAM-1 50%
• E-Selectin 50%
• Normal Human 16%
• Human Immunodeficiency Virus Infection 16%
• Lipid Blood Level 16%
• Viral Load 16%